• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics and pharmacodynamics of organic nitrates.

作者信息

Fung H L

机构信息

Department of Pharmaceutics, School of Pharmacy, State University of New York, Buffalo 14260.

出版信息

Am J Cardiol. 1987 Nov 16;60(15):4H-9H. doi: 10.1016/0002-9149(87)90543-1.

DOI:10.1016/0002-9149(87)90543-1
PMID:3120565
Abstract

The pharmacokinetic and pharmacodynamic aspects of organic nitrates are discussed, with particular emphasis on the 3 major organic nitrates currently in use, nitroglycerin (NTG), isosorbide dinitrate and isosorbide-5-mononitrate. After intravenous administration, both NTG and isosorbide dinitrate exhibit large systemic clearances and both nitrates appear to be extensively distributed in vascular and other peripheral tissues. Two pharmacokinetic features appear particularly notable for NTG: there is a significant arteriovenous extraction of the drug, and its systemic clearance is related to cardiac output. Both of these features, plus other evidence, suggest that organic nitrates may be substantially removed from the systemic circulation by the vasculature itself. During nitrate tolerance, plasma drug concentrations remain elevated, but vascular activity is diminished. This apparent paradox might be explainable by a unifying hypothesis of reduced nitrate metabolism during vascular tolerance; thus, in the tolerant state, reduced systemic clearance of the intact drug brought about elevated plasma concentrations, whereas reduced cellular metabolism at the smooth muscle brought about a decrease in vascular activity. The complex relations among plasma kinetics, vascular metabolism and pharmacologic action of organic nitrates are still poorly understood.

摘要

相似文献

1
Pharmacokinetics and pharmacodynamics of organic nitrates.
Am J Cardiol. 1987 Nov 16;60(15):4H-9H. doi: 10.1016/0002-9149(87)90543-1.
2
Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates.
Clin Pharmacokinet. 1988 Jul;15(1):32-43. doi: 10.2165/00003088-198815010-00003.
3
Clinical pharmacokinetics of nitrates.硝酸盐的临床药代动力学
Cardiovasc Drugs Ther. 1994 Oct;8(5):693-9. doi: 10.1007/BF00877116.
4
Clinical pharmacokinetics of organic nitrates.有机硝酸盐的临床药代动力学
Clin Pharmacokinet. 1983 Sep-Oct;8(5):410-21. doi: 10.2165/00003088-198308050-00003.
5
Pharmacokinetics of nitroglycerin and long-acting nitrate esters.硝酸甘油和长效硝酸酯类药物的药代动力学
Am J Med. 1983 Jun 27;74(6B):13-20. doi: 10.1016/0002-9343(83)90849-5.
6
Nitrates in the elderly. Pharmacological considerations.
Drugs Aging. 1992 Jan-Feb;2(1):14-9. doi: 10.2165/00002512-199202010-00003.
7
Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.硝酸异山梨酯和5-单硝酸异山梨酯的药代动力学。
Int J Clin Pharmacol Ther Toxicol. 1989 Sep;27(9):445-53.
8
Pharmacokinetics of organic nitrates in man: an overview.人体中有机硝酸盐的药代动力学:综述。
Eur Heart J. 1988 Jan;9 Suppl A:33-7. doi: 10.1093/eurheartj/9.suppl_a.33.
9
Blood vessel uptake and metabolism of organic nitrates in the rat.大鼠体内有机硝酸盐的血管摄取与代谢
J Pharmacol Exp Ther. 1984 Feb;228(2):334-41.
10
Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.硝酸甘油和有机硝酸盐。给药方法的选择。
Drugs. 1987 Sep;34(3):391-403. doi: 10.2165/00003495-198734030-00005.

引用本文的文献

1
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).心力衰竭患者药物的临床药代动力学:更新(第 1 部分,静脉内给药的药物)。
Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2.
2
Aortic and coronary artery dissection during percutaneous coronary intervention: a case report and review article.经皮冠状动脉介入治疗期间的主动脉和冠状动脉夹层:病例报告和综述文章。
Clin Cardiol. 2011 May;34(5):283-6. doi: 10.1002/clc.20890. Epub 2011 Apr 27.
3
Nitrate tolerance and the links with endothelial dysfunction and oxidative stress.
硝酸盐耐受性及其与内皮功能障碍和氧化应激的联系。
Br J Clin Pharmacol. 2003 Dec;56(6):620-8. doi: 10.1046/j.1365-2125.2003.01946.x.
4
Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.冠心病患者在急性和持续应用硝酸异山梨酯治疗期间,对与异山梨酯结合的NO2血浆浓度变化的反应。
Clin Cardiol. 2000 Jun;23(6):427-32. doi: 10.1002/clc.4960230610.
5
Clinical pharmacokinetics of vasodilators. Part II.血管扩张剂的临床药代动力学。第二部分。
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
6
Causes and problems of nonresponse or poor response to drugs.药物无反应或反应不佳的原因及问题。
Drugs. 1996 Apr;51(4):552-70. doi: 10.2165/00003495-199651040-00004.
7
Pharmacokinetic characterisation of transdermal delivery systems.透皮给药系统的药代动力学特征
Clin Pharmacokinet. 1994 Feb;26(2):121-34. doi: 10.2165/00003088-199426020-00005.
8
Clinical pharmacokinetics of nitrates.硝酸盐的临床药代动力学
Cardiovasc Drugs Ther. 1994 Oct;8(5):693-9. doi: 10.1007/BF00877116.
9
Nitrate tolerance. A review of the evidence.硝酸盐耐受性。证据综述。
Drugs. 1989 Apr;37(4):523-50. doi: 10.2165/00003495-198937040-00006.
10
Mechanisms of nitrate tolerance: a review.硝酸盐耐受性的机制:综述
Cardiovasc Drugs Ther. 1990 Feb;4(1):247-52. doi: 10.1007/BF01857640.